Ir(III) Diamine Transfer Hydrogenation Catalysts in Cancer Cells

Abstract

The development of catalytic metallodrugs is an emerging field which may offer new approaches to cancer chemotherapeutic design. By exploiting the unique properties of transition metal complexes, in‐cell catalysis can be applied to modulate cellular redox balance as part of a multi‐targeting mechanism of action. We describe the synthesis and characterisation of six coordinatively unsaturated iridium(III) diamine catalysts which are stable at physiological pH in aqueous solution. Reduction of the colorimetric substrate 2,6‐dichlorophenolindophenol by transfer hydrogenation under biologically compatible conditions achieved turnover frequencies up to 63 ± 2 h‐1 and demonstrated that the source of hydride (sodium formate) is the limiting reagent, despite being in a thousandfold excess of the catalyst. The catalyst showed low in vivo acute toxicity in zebrafish embryos, and modest in vitro potency towards cancer cells. When administered alone, the catalyst generated oxidative stress in cells (an effect which was conserved in vivo) but co‐treatment with a non‐toxic dose of sodium formate negated this effect. Co‐treatment with sodium formate significantly enhanced catalyst potency in cancer cells (A2780 ovarian and MCF7 breast cancer cells) and drug‐resistant cells (A2780cis and MCF7‐TAMR1) but not in non‐tumorigenic cells (MRC5), demonstrating that a redox‐targeting mechanism may generate selectivity for cancer cells.